Table 2.

DMD ranking on safety attributes by experts (higher scores indicate better ranking)

Safety attributes	Scoring
	Cladribine tablets	Fingolimod	Natalizumab	Ocrelizumab	Alemtuzumab
Availability of long-term safety data	7.5	6.5	8.1	7.2	7.2
Low risk of malignancy	7.3	6.6	6.4	6.8	5.8
Good benefit vs. risk profile	7.4	5.7	7.3	6.9	6.2
Good short- and long-term safety profile	7.7	5.8	6.7	6.8	5.8
Low risk of PML	7.9	5.9	5.4	7.2	6.8
Relatively well tolerated	7.5	6.8	7.0	7.8	6.2

DMD disease-modifying drug, PML progressive multifocal leukoencephalopathy